Akeso Inc. 康方生物（9926.HK）

A phase 3 study (AK104-308) of #cadonilimab (PD-1/CTLA-4) in combination with lenvatinib and transarterial chemoembolization (TACE) for unresectable, nonmetastatic #hepatocellularcarcinoma (#HCC) has enrolled its first patient. Based on promising phase 2 clinical results published at #ASCOGI 2024，we have progressed to phase 3 trials for advanced uHCC. Simultaneously, a phase 3 trial evaluating cadonilimab as adjuvant therapy for hepatocellular carcinoma after curative resection is also underway. #cadonilimab #HCC #immunotherapy

First patient enrollment in the US completed for the phase II clinical trial of Akeso's innovative #CD47 monoclonal antibody, # (#AK117), in combination with azacitidine for patients with MDS. Commencing this international study, we're addressing the critical need for innovative MDS therapies and supported by our steadfast commitment to strategic product development. #CD47 #AK117 #ligufalimab #immunology #MDS  #Akeso https://lnkd.in/gs4K3jNg

💖 Congratulations to our partner, Summit Therapeutics, Inc.on this incredible collaboration with MD Anderson Cancer Center! We are eagerly anticipating the global availability of this immunotherapy and anti-angiogenic standards therapy for the benefit of patients worldwide!

#Cadonilimab (PD-1/CTLA-4 bispecific antibody) is increasingly being explored in oncology as a cornerstone immunotherapy drug in combination therapies, particularly for PD-1-resistant diseases with critical clinical needs. First patient enrollment has been completed in the Phase 3 clinical study (AK109-301) evaluating cadonilimab in combination with a VEGFR-2 monoclonal antibody and chemotherapy for the treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who failed immunochemotherapy. #cadonilimab #gastriccancer #immunology

We are excited to announce that the supplemental biologics license application for the first-in-class PD-1/VEGF bispecific antibody drug, #依达方® (#ivonescimab Injection), as a monotherapy for first-line treatment of PD-L1 positive (PD-L1 TPS≥1%) locally advanced or metastatic non-small cell lung cancer (#NSCLC), has been accepted by the NMPA. https://lnkd.in/gWQESt6e

#Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy https://lnkd.in/gyRvCfir

First-line treatment with ivonescimab (AK112; SMT112) monotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) monotherapy in patients with locally advanced or metastatic, PD-L1–positive non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 HARMONi-2 trial (NCT05499390)OncLive https://lnkd.in/gj-HGWQP

Positive interim analysis results from the Phase 3 trial of Akeso's #cadonilimab (PD-1/CTLA-4 BsAb) plus chemo as first-line treatment for advanced gastric cancer presented at 2024 AACR https://lnkd.in/ga4Gu-VN

With a longer median mPFS of 7.6 months compared to 4.2 months for chemotherapy alone, and a higher ORR of 71% versus 44%, the combination of #penpulimab and chemotherapy has become the world's first randomized, multicenter, placebo-controlled, phase III study for first-line treatment of squamous lung cancer. The study also showed a 30-month OS rate of over 50% (51.6%). This study was published at #TheLancetRespiratoryMedicine https://lnkd.in/gDuB3qjm

Celebrating the year of the #Dragon2024！